Tempus AI (NASDAQ:TEM - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Friday, August 8th. Analysts expect Tempus AI to post earnings of ($0.23) per share and revenue of $296.84 million for the quarter. Tempus AI has set its FY 2025 guidance at EPS.
Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. Tempus AI had a negative return on equity of 533.21% and a negative net margin of 88.27%. The company had revenue of $255.74 million for the quarter, compared to the consensus estimate of $248.13 million. The firm's quarterly revenue was up 75.4% compared to the same quarter last year. On average, analysts expect Tempus AI to post $-6 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Tempus AI Stock Up 2.6%
Tempus AI stock traded up $1.40 during midday trading on Monday, reaching $56.29. The stock had a trading volume of 2,882,644 shares, compared to its average volume of 12,470,841. Tempus AI has a 12 month low of $31.36 and a 12 month high of $91.45. The company has a market capitalization of $9.75 billion, a P/E ratio of -7.23 and a beta of 4.98. The company has a fifty day moving average price of $62.47 and a two-hundred day moving average price of $57.61. The company has a current ratio of 1.71, a quick ratio of 1.56 and a debt-to-equity ratio of 2.45.
Analyst Ratings Changes
TEM has been the topic of several research analyst reports. Piper Sandler upped their price objective on Tempus AI from $55.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, May 15th. Guggenheim upped their price objective on Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Bank of America upped their price objective on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a research note on Wednesday, June 25th. BTIG Research began coverage on Tempus AI in a report on Monday, April 21st. They issued a "buy" rating and a $60.00 price target for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $70.00 price target on shares of Tempus AI in a research report on Wednesday, May 7th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $65.09.
Check Out Our Latest Analysis on TEM
Insider Activity
In other Tempus AI news, EVP Erik Phelps sold 51,317 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $72.56, for a total transaction of $3,723,561.52. Following the completion of the sale, the executive vice president directly owned 97,779 shares in the company, valued at approximately $7,094,844.24. The trade was a 34.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Ryan Fukushima sold 20,000 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $52.36, for a total transaction of $1,047,200.00. Following the sale, the chief operating officer owned 884,460 shares of the company's stock, valued at approximately $46,310,325.60. This represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 778,772 shares of company stock valued at $52,052,375. 27.60% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tempus AI stock. Rhumbline Advisers purchased a new position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,405 shares of the company's stock, valued at approximately $116,000. Institutional investors and hedge funds own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.